drugset / Trial / NCT00074334
TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma
Phase 1/2
Terminated
3 enrolled
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: The TP-38 toxin can locate tumor cells and kill them without harming normal cells. Giving TP-38 toxin directly into the tumor may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of TP-38 toxin administered directly into the brain and to see how well it works in treating young patients with recurrent or progressive supratentorial high-grade glioma.
Timeline
- Start
- 2004-05
- Primary completion
- 2006-06
- Completion
- 2006-06
Outcome
Outcome not reported
Stopped: “Drug company withdrawal of support for investigational agent in this indication.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TP-38 | Protein / enzyme biologic | — | Other |